The FCF Biotech Venture Capital Monitor – USA is a monthly published overview of venture capital trends in the US-Biotech sector.
As of the end of December 2023, we identify the following current VC trends in the US-Biotech sector:
- In 2023, overall Biotech funding in the USA has reached USD 23,607m
- Compared to December 2022 the financing volume decreased by roughly 26% (31,894m vs. 23,607m)
- The top 5 deals exceed USD 273m each, the largest transaction amounted to USD 401m with ElevateBio
- Bicara Therapeutics has the highest transaction Volume of USD 165m in December, followed by Lyndra Therapeutics USD 123m and Tome Biosciences USD 118m
- ARCH Venture Partners (USA) is leading the Top 5 Investors (by deal volume), followed by RA Capital Management (USA) and OrbiMed (USA)
- As an indication oncology records the highest investment activity
Capital Markets Research
We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:
Venture Capital
Licensing
Healthcare & Life Sciences Venture Capital Monitor – Europe Monthly Venture capital activities in the European Life Sciences sector
Biotech Venture Capital Monitor – USAMonthly Venture capital activities in the US Life Sciences sector
Life Sciences Venture Capital ReportRecent Venture capital trends in the European Life Sciences sector
Other Research
Life Sciences IPO ReportRecent IPO trends in the Life Sciences sector
Biotech Public Equity MonitorRecent valuations of listed European Life Sciences companies
MedTech & Diagnostics Public Equity MonitorRecent valuations of listed MedTech companies
Life Sciences SPAC MonitorPerformance overview of merged Life Sciences SPACs
NEWS
FCF Biotech Venture Capital Monitor – USA 12/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 12/2023”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 12/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 12/2023”. The Monitor is a monthly published overview of venture capital trends in the European
FCF Biotech Venture Capital Monitor – USA 11/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 11/2023”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 11/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 11/2023”. The Monitor is a monthly published overview of venture capital trends in the European
FCF Biotech Venture Capital Monitor – USA 10/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 10/2023”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As